Inactivation of PTEN has been shown to occur within 40% of HER2+ breast cancer patients and has been correlated with poor prognosis, as well as, adaption of mesenchymal characteristics in vitro[8, 9]. This evidence concerns the gene ERBB2 and breast carcinoma.